PhaseⅡstudy of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Meta‑analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S‑1 plus cisplatin (SP) as first‑line treatment for advanced gastric cancer

Phase I dose‑escalation study on irinotecan, cisplatin, and S‑1 combination in chemotherapy‑naïve patients with HER2‑negative advanced gastric cancer (HERBIS‑4B, OGSG 1106)

Effect of the number of cycles of docetaxel + S‑1 therapy on long‑term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials

TRESBIEN (OGSG 2101) Encorafenib, binimetinib and cetuximab for early recurrent Stage II/III BRAF V600E-mutated CRC

Histology classification highlights the difference in the effectiveness of S-1 over capecitabine when combined with cisplatin in patients with HER2-negative unresectable advanced or recurrent gastric cancer with measurable disease

Efficacy of SP and XP for HER2-negative unresectable advanced recurrent gastric cancer varies by histologic type

進行胃癌一次治療におけるSP対XPの無作為化試験のメタ解析

Efficacy of SP and XP for HER2-negative unresectable advanced recurrent gastric cancer varies by histologic type

Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy OGSG1201